Background: Image-guided percutaneous radiofrequency ablation (RFA) has been proposed as an efficacious local therapy for lung metastases in nonsurgical candidates. Reports of long-term outcome from this treatment have been limited.
introduction
The lung is one of the most common site of metastasis in malignant diseases. It is estimated that lung metastases occur in up to 30% of patients with metastatic adenocarcinoma primary tumors [1] . Majority of patients with lung metastases have multiple lung lesions or have disseminated disease at other distant sites. These patients are treated palliatively with systemic therapies primarily aimed at disease control or with radiotherapy for symptom control. In certain instances, lung metastases may exist in isolation for which intervening with aggressive treatment approach may improve survival. In metastatic colorectal cancer, modern systemic chemotherapy using irinotecan-based regimen in combination with biological therapy using bevacizumab has been shown to improve survival, achieving a median survival time of 20 months [2] . After cytoreductive nephrectomy, patients with metastatic renal cell carcinoma have been shown to achieve a median survival of 11 months when treated with interferon (IFN) therapy [3] . The preliminary results of an ongoing phase III randomized trial of sunitinib malate (SU11248) versus IFN-a as first-line systemic therapy for patients with metastatic renal cell carcinoma has also demonstrated a significant improvement in progressionfree survival for patients treated with sunitinib [4] . This progress made in systemic therapies has been a major advancement in cancer research. However, 5-year survivors from systemic therapy alone are rare. Recent interest has focused on combining local and systemic therapies to target macroscopic metastatic tumor in the era where effective systemic therapies are available which may address the microscopic disease. This strategy has the potential to significantly improve long-term survival results.
Pulmonary metastasectomy as a surgical procedure with proven therapeutic value in selected patients is now becoming increasingly accepted as a treatment option. The International Registry of Lung Metastases, a cooperative multicentric clinical study, reported the outcomes of 5206 patients with lung metastases treated by pulmonary metastasectomy. In this registry, epithelial tumors and sarcomas formed the majority constituting up 43% and 41% of cases, respectively. Forty-six percent of patients treated had single lesions and the actuarial survival achieved after complete metastasectomy was 36% at 5 years [5] . Radiofrequency ablation (RFA) is a promising treatment for patients with lung metastases not amendable to surgery. Moreover, it is an appropriate modality for patients who refuse surgery or are at high risk of post-thoracotomy morbidity. This procedure is carried out by inserting a conductive probe into the tumor under image guidance and applying high-frequency alternating current that leads to tissue coagulative necrosis [6] . A recent systematic review reported 17 institutional series for which treatment of pulmonary metastases by RFA achieved procedure-related morbidity rate ranging from 15.2% to 55.6%, mortality rate ranging from 0% to 5.6% and 3-year survival rates ranging between 15% and 46% [7] .
Our ongoing open-labeled prospective trial of RFA for pulmonary metastases is now over 9 years old and has accrued a large number of patients who were uniformly treated according to the institution's protocol. A previous report has ascertained the safety of this procedure and reported that chest drain placement secondary to pneumothorax or effusion represents the most common major complication [8] . Based on the preliminary data that reported an acceptable complication rate, we expanded the trial to enroll more patients with pulmonary metastases for treatment. With a long-term followup, the purpose of the current study seeks to determine its long-term efficacy.
patients and methods
RFA for pulmonary metastases was initiated and carried out under an institutional review board-approved open-labeled-type trial. Since its initiation in November 2000, a total of 148 patients with primary and secondary lung tumors were treated. Patients with lung tumors were evaluated for RFA by a multidisciplinary team comprising surgical oncologists, medical oncologists and a radiologist. Specific inclusion criteria consisted of (i) age between 18 and 85 years; (ii) patients with early-stage non-small-cell lung carcinoma pulmonary metastases evaluated by thoracic surgeons at our institution and precluded from surgery because of poor pulmonary function with forced expiratory volume in 1 s less than l, cardiac risk with New York Heart Association Class of 3 or greater or poor performance status of two or greater with Eastern Cooperative Oncology Group performance and (iii) patient refusing to undergo surgery. Exclusion criteria included the following: (i) diameter of metastases >5 cm; (ii) greater than six lesions per hemithorax; (iii) lesions immediately adjacent to major pulmonary vessels; (iv) lesions located immediately adjacent to the pulmonary hilum of the lung; (v) lesions immediately adjacent to major bronchi and (vi) bleeding disorders not responding to medical treatment.
percutaneous RFA protocol
All RFA procedures were carried out under fluoro-CT guidance by an interventional radiologist (DG). The CT machine (Xpress SX; Toshiba, Tokyo, Japan) coupled with a Rita 1500 generator (Rita Medical, Mountain View, CA) enabled real-time imaging display, along with temperature, power and impedance. The patients' vital signs were monitored continuously during the procedure. Patients were positioned on the CT table according to the location of their metastases. For tumors in the anterior chest cavity, the position adopted was supine to facilitate an anterior approach. For tumors located in the posterior chest, patients were positioned in the prone position for a posterior approach.
Midazolam was administered intravenously to achieve light sedation. Under local anesthetic (Xylocaine 1%), a Rita Starburst XL probe was inserted percutaneously into the lung and advanced toward the lesion under fluoro-CT guidance. The length of the 14-gauge probe was of either 10 or 15 cm. Once the probe was correctly positioned in the lesion, the tines were deployed. Lesions >3 cm in diameter required overlapping ablation fields. The initial power setting was 35 W. The ablation algorithm was gradually increased to 150 W with incremental probe deployment to achieve the desired target temperature of 90°C. The temperature was maintained at a fixed time depending on lesion size according to a fixed protocol. Lesions of 3, 4 and 5 cm were maintained for 15, 20, and 37 min, respectively. Ablation of the insertion tract was carried out upon withdrawal of the probe to prevent seeding of tumor cells.
post-procedural management
Patients were admitted in hospital for at least 1 day for observation. A chest X-ray was carried out 1 h after the procedure and again just before discharge to exclude pneumothorax. Patients who had large or clinically significant pneumothorax required chest drains. Small and asymptomatic pneumothorax was managed conservatively.
follow-up
All patients were followed up every 3 months. Helical contrast-enhanced computed tomography (CT) was carried out every 6 months. The primary study end point was from the time of treatment to the time of death (overall survival). Follow-up data were obtained from the referring physicians and phone calls and/or emails from the patients. Response to RFA was evaluated 6 months posttreatment chest CT according to previously described modified RECIST criteria, where complete response (CR) was where the target lesion demonstrated cavitations, necrosis and cyst formation with a 25% reduction in size; partial response (PR) was where the target lesion demonstrated necrosis with liquid density in the central component or there was >30% reduction in the longest diameter; stable disease (SD) was where the target lesion demonstrated <30% reduction in the longest diameter or maintained a solid appearance without central necrosis or cavitations; and progressive disease (PD) was where the target lesion increased by >20% in size and maintained a solid mass with invasion of adjacent structures [9] .
statistical analysis
The data collected were analyzed using SPSSÒ for Windows version 15.0 (SPSS, Munich, Germany). The patient characteristics were reported using frequency and descriptive analyses. The Kaplan-Meier method was used to analyze survival. Univariate analysis (log rank) was carried out to determine the clinicopathological factors affecting survival. The following variables were examined: age, sex, number of lesions, size of the largest lesion, extent of lung involvement, tumor location, disease-free interval, primary tumor type and response to treatment. Multivariate analysis was carried out on all factors (P < 0.10) using the Cox proportional hazards regression model. The median time to death was defined as the time where 50% of patients have died. Follow-up was calculated from the date of treatment to the date of last follow-up. P value of <0.05 was considered statistically significant.
results patient sample and treatment characteristics
One hundred and eighty-eight RFA procedures were carried out in 148 patients. patients (15%) had two, 2 patients (1%) had three, and 4 patients (3%) had four RFA procedures for persistent or recurrent disease. The median follow-up time for all patients was 29 months (range, 2-103).
analysis of complications
The median length of hospital stay was 2 days (range, 1-16).
There was no treatment-related mortality. Sixty-six patients (45%) developed a pneumothorax after the procedure, 16 patients (11%) had a pleural effusion, 10 patients (7%) had consolidation, 1 patient (1%) developed bleeding and 12 patients (8%) had pleuritic chest pains. Chest tube placement as an intervention for RFA-related complications was required in 45 patients (30%) of which one patient developed severe consolidation and a lung abscess with associated empyema requiring a wedge resection and decortication. Univariate analysis to determine patient-and treatment-related characteristics associated with complications requiring chest tube intervention identified ablation time (ablation time £50 min 20% and >50 min 42%; P = 0.004), impedance required to achieve tumor ablation (impedance £300 W 20% and >300 W 39%; P = 0.012), number of lesions (two or fewer in 18% and more than two in 59%; P < 0.001), tumor location (hilar 55% and nonhilar 26%; P = 0.012) and extent of lung involvement (unilateral 22%, bilateral 51%; P = 0.001). From multivariate analysis, the number of lesions more than two was identified as the sole independent predictor for complication requiring chest tube intervention [hazard ratio (HR) = 4.6, 95% confidence interval (CI) 1.5-13.6; P = 0.006].
analysis of long-term efficacy
Objective response to treatment was observed in 68 patients (46%), of which 38 patents (26%) had a CR and 30 patients (20%) had a PR. Amongst the nonresponders, 57 patients (39%) had SD and 23 patients (16%) had PD. The only factor identified to predict response to treatment was having undergone prior surgery for lung metastases (responders who had no surgery 43% and those who had surgery 68%; P = 0.048). The median progression-free survival was 11 months (95% CI 9-14). The median overall survival and 3-and 5-year survivals were 51 months (95% CI 19-83) and 60% and 45%, respectively ( Figure 1 ). Factors associated with progression-free and overall survival identified through a univariate analysis are shown in Table 2 . From the multivariate analysis, disease-free interval (HR = 0.4, 95% CI 0.2-0.8; P = 0.013) and response to treatment (HR = 2.5, 95% CI 1.4-4.5; P = 0.002) were independent predictors for overall survival (Figures 2 and 3) .
pattern of treatment failure after RFA One hundred and eighteen patients (80%) developed disease progression after RFA treatment. The site of disease progression was identified to be local around the previous ablation site in five patients (4%), in other parts of the lung in 38 patients (32%), in the lung and at other distant sites in 35 patients (30%) and at other distant sites only in 40 patients (34%). Twentyeight patients (19%) underwent repeat RFA treatment as part of disease treatment or control. In these 28 patients, the median overall survival from the first RFA procedure was 81 months.
discussion
The purpose of RFA for lung metastases serves not as an alternative approach to pulmonary metastasectomy. Pulmonary metastasectomy has been shown to achieve 5-and 10-year survival of 36% and 26%, respectively, and remains the standard of care for patients with resectable lung metastases. It is technically feasible using either an open thoracotomy or more popularly now through the video-assisted thorascopic approach with low morbidity and mortality [10] . Unfortunately, surgery is not a feasible option in majority of patients with lung metastases given that they usually present [11] . It is only within this highly selected patient population that pulmonary metastasectomy may be a worthwhile treatment option. RFA is a versatile alternative available to patients who are deemed to be at a high risk of morbidity secondary to thoracotomy, for those who refuse surgery and for those who are beyond the selection criteria for pulmonary metastasectomy. It may be used in patients as an alternative to surgery as a curative procedure, or who have multiple metastases to expand the number of possibly treated lesions in patients undergoing surgery [12] , to control slowly growing lesions or to palliate symptomatic lesions. All these purposes may be achieved concurrently with other treatment modality including systemic therapies, surgery and radiotherapy. Our results demonstrate that long-term survival is a reality after RFA treatment of lung metastases with an 'oncological cure' defined as 5-year survival being achieved in 45% of patients. This result is comparable with the long-term survival results of pulmonary metastasectomy for various metastatic presentations including colorectal cancer, renal cell carcinoma, soft tissue sarcoma and melanoma, where 5-year survival ranges between 27% and 68% [13] [14] [15] [16] [17] . In patients who were objective responders, having CR or PR, the 5-year survival approached 60%. This allows us to draw comparison and indicates that in patients who achieve an objective response with RFA, the results are equivalent to surgical metastasectomy. However, 54% of patients treated were nonresponders. Our analysis identified previous surgery for lung metastases as a factor associated with response, indicating that RFA may be employed to treat recurrence successfully after prior lung resection. It would be especially useful at this time, given that the survival results after repeat pulmonary metastasectomy are often poorer and pose an increased risk of procedure-related morbidity [18] . In the analysis for overall survival, univariate analysis identified bilateral lung involvement and peripheral tumors and responders to treatment were associated with improved overall survival. The lack of association between bilateral lung tumors for which one would assume to predict a poorer outcome indicates that RFA may be employed in bilateral tumors. Undergoing ablation of bilateral tumors similarly did not appear to influence a major complication that required chest tube intervention, rather so, chest tube intervention was related to the number of lesions ablated. The association of peripheral tumors alludes to the fact that there is less propensity of lymph node metastases compared with central tumors [19] . Hence, this explains the more favorable survival demonstrated by our data. Likewise, results from metastasectomy studies have demonstrated that involvement of hilar or mediastinal lymph nodes carries a poor prognosis. In an institutional experience of 245 patients of whom 114 patients had lung metastases from colorectal cancer and 62 patients from renal cell carcinoma, after a complete metastasectomy and lymphadenectomy, the median survival in patients without lymph node metastasis (N0) was 64 months, pulmonary/hilar lymph nodes only (N1) was 33 months and pulmonary/hilar with mediastinal lymph node (N2) was 21 months (N0 versus N1 P = 0.018, N0 versus N2 P < 0.001) [20] . This finding indicates that nodal involvement predicts a poorer outcome, with the outcomes of patients with nodal involvement being further predicted by the level of thoracic lymph nodes involved. In a similar study evaluating experience of pulmonary metastasectomy of which 70 of 883 patients underwent complete lymphadenectomy, the 3-year survival was 69% in lymph node-negative patients compared with 38% in lymph node-positive patients [21] . Given that majority of patients with lung metastases who are considered for curative therapies commonly have colorectal or renal cell origin cancers, the inferior outcome achieved even after lymphadenectomy in patients with node-positive disease questions the appropriateness of this therapy [22] . This is especially so in an era of effective modern systemic therapies, where its application as an induction/neo-adjuvant treatment before local therapy may therefore appear to be a better treatment strategy to allow a 'test of time'.
In the analysis of treatment failure, disease progression inevitably occurred in majority of patients (80%), of which local recurrence of the ablation site occurred in five patients (4%). Only one of five patients had a 5-cm tumor, the remaining four had tumors 4 cm or less in diameter. To avoid local recurrence, it must be emphasized that there is a need to avoid treating tumors >5 cm and also to adequately maintain ablation time to ensure thorough tumor destruction. Thirty two percent of patients developed recurrence in other parts of the lung and 30% at other distant metastatic sites. In the analysis of factors associated with progression-free survival, only response to treatment correlated with progression-free survival outcome. There were no other treatment-related variables that could predict for progression-free survival.
Hence, it appears that RFA may be useful in controlling lung tumor growth, but as a monotherapy may not be sufficient to achieve disease-free survival. This reiterates the importance of combining local therapy with systemic therapies to improve disease control in patients with metastatic disease. RFA was also employed as a treatment of lung tumors in 28 patients who developed progression after previous RFA treatment and was shown to achieve a median survival of 81 months, demonstrating the ability of this treatment modality in prolonging survival through repeated local therapy.
It must be acknowledged that although the modified RECIST criteria [9] was described to evaluate response of tumors after RFA, it possess certain limitations in itself. It has been recognized that following RFA treatment, a lesion followed on imaging scans often undergoes a characteristic course of lesion enlargement and then involution over an indefinite time period before the initial inflammatory response from thermal ablation regresses to became consolidated as a fibrotic scar. This arbitrary timing of postablation changes is a weakness in the assessment of response from RFA. Our pneumothorax rates and chest tube requirement rates for management of post-RFA complications (i.e. pneumothorax, pleural effusion) appear to be higher than those previously reported in other series [23, 24] ; however, we believe that this is a result of our treating multiple lesions and our low threshold of initiating chest tube insertion for patients with pneumothoracies. 
